Daygen L. Finch
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Cancer Genomics and Diagnostics, Bladder and Urothelial Cancer Treatments, Molecular Biology Techniques and Applications, Radiopharmaceutical Chemistry and Applications
Most-Cited Works
- → Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer(2018)512 cited
- → Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial(2019)342 cited
- → Extrapulmonary small cell cancer(2006)123 cited
- → Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T‐cell lymphoma(2014)105 cited
- → Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer(2024)103 cited
- → Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma(2010)99 cited
- → Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition(2021)92 cited
- → Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy(2010)78 cited
- → Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial(2023)71 cited
- → Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial(2018)71 cited